Russian Journal of Skin and Venereal DiseasesRussian Journal of Skin and Venereal Diseases1560-95882412-9097Eco-Vector3697410.17816/dv36974Research ArticleThe hand-foot syndrome in oncological patients receiving chemotherapyOrlovaEkaterina V.assistentkolip7@mail.ruBelousovaT. A-GrabovskayaO. V-SevidovaL. Yu-BagirovaA. Aayna_bagirova@mail.ruI.M. Setchenov First Moscow State Medical University15102015185212521072020Copyright © 2015, Eco-Vector2015Side effects of chemotherapy in cancer patients treated by fotemustin are described, manifesting by the hand-foot syndrome - ulcerative necrotic polymorphic dermal angiitis.hand-foot syndromechemotherapypolymorphic dermal angiitisfotemustinладонно-подошвенный синдромхимиотерапияполиморфно-дермальный ангиитфотемустин[Beveridge R.A., Kales A.N., Binder R.A., Miller J.A., Virts S.G. Pyridoxine (B6) and amelioration of hand/foot syndrome. Proc. Am. Soc. Clin. Oncol. 1990; 9 (Suppl): 102a.][Yarbro C.H., Frogge M.H., Goodman M. Cancer symptom management. Sudbury: Jones and Bartlett Publishers; 2004.][Gabizon A., Goldenhersh M.A., Hubert A., Ingber A., Lotem M., Peretz T., Gabizon A. Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Arch. Dermatol. 2000; 136(12): 1475-80.][Lorusso D., Di Stefano A., Carone V., Fagotti A., Pisconti S., Scambia G. Pegylated liposomal doxorubicin-related palmarplantar erythrodysesthesia («hand-foot»-syndrome). Ann. Oncol. 2007; 18(7): 1159-64.][Martschick A., Sehouli J., Patzelt A., Richter H., Jacobi U., Oskay-Ozcelik G., et al. The pathogenetic mechanism of anthracycline-induced palmar-plantar erythrodysesthesia. Anticancer Res. 2009; 29(6): 2307-13.][Болотина Л.В., Горбунова В.А., Кононенко И.Б., Моисеенко В.М., Орлова Е.В. и др. В сб.: Практические рекомендации по лечению злокачественных опухолей и практические рекомендации по поддерживающей терапии в онкологии. М.: RUSSCO; 2014: 371-4.][Gressett S.M., Stanford B.L., Hardwicke F. Management of hand-foot syndrome induced by capecitabine. J. Oncol. Pharm. Pract. 2006; 12(3): 131-41.][Lipworth A.D., Robert C., Zhu A.X. Hand-foot syndrome (handfoot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology. 2009; 77(5): 257-71. doi: 10.1159/000258880.][Kara I.O., Sahin B., Erkisi M. Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction. Breast. 2006; 15(3): 414-24.][Mangili G., Petrone M., Gentile C., De Marzi P., Vigano R., Rabaiotti E. Prevention strategies in palmar-plantar erythrodysesthesia onset: The role of regional cooling. Gynecol. Oncol. 2008; 108(2): 332-35.]